If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
ARYA Sciences Acquisition III (ARYA)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
Duck Creek Technologies, Inc. (DCT)
Priced IPO
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
More companies

Akouos, Inc. (AKUS)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a precision genetic medicine company dedicated to their mission of developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss. They have built a precision genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus, or AAV, and a novel delivery approach. They are executing on their core strategic initiatives, which include the advancement of their lead product candidate, AK-OTOF, expansion of their pipeline, and development of internal manufacturing capabilities and, ultimately, a commercial infrastructure. Their aim is to leverage their capabilities to become a fully integrated biotechnology company. They believe their platform and their team together provide a unique advantage to efficiently develop potential genetic medicines for a variety of inner ear disorders. Hearing loss is one of the world's largest unmet medical needs. Approximately 466 million people around the world, including 34 million children, live with disabling hearing loss, and a growing body of evidence suggests hearing loss can have a significant impact on cognitive development, psychiatric health, and healthy aging. They estimate that AK-OTOF has a potential addressable population of up to approximately 7,000 individuals, which is a subset of the total population of individuals with hearing loss due to mutations in the otoferlin, or OTOF, gene in the United States and European Union in the aggregate.
Emmanuel Simons -
Employees Founded
57 2016


Address: 645 Summer Street, Suite 200, Boston, MA 02210, US

Telephone: (857) 410-1818

Web page:

IPO information

Expected Date 6/26/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $14.00-$16.00
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $552.2
Revenues (MM) $0
Net Income (Loss) (MM) $-30.3


What do you think will happen with the AKUS share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 8.3
Shares Revised (MM) 12.5
Expected offer amount (MM) $124.5
Realized offer amount(MM) $212.5
BofA Securities/ Cowen/ Piper Sandler

Sector: Healthcare

Tweets about $AKUS

Tweets volume:

RT volume:


Google Trends Stats